# Single-centre Study of Everolimus as GvHD Prophylaxis After Post-Transplantation Cyclophosphamide After Allogeneic SCT

> **NCT02812940** · PHASE2 · COMPLETED · sponsor: **University of Cologne** · enrollment: 19 (actual)

## Conditions studied

- Graft-versus-Host Disease

## Interventions

- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT02812940
- **Lead sponsor:** University of Cologne
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2019-07
- **Final completion:** 2020-12
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2021-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02812940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02812940, "Single-centre Study of Everolimus as GvHD Prophylaxis After Post-Transplantation Cyclophosphamide After Allogeneic SCT". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02812940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*